<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902445</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0329</org_study_id>
    <nct_id>NCT02902445</nct_id>
  </id_info>
  <brief_title>Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation)</brief_title>
  <acronym>Gastrovimc</acronym>
  <official_title>Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation) Evaluation of Individual Genetic Susceptibility in Severe Gastro-enteritis Rotavirus: Role of HBGA Polymorphisms &amp; Biotechnology Improvement of RVA Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GASTROVIM research explores the links between individual genetic susceptibility, genetic&#xD;
      variability of rotavirus strains and effectiveness of immunization with the rotavirus&#xD;
      vaccination: a clinical investigation to assess glycan attachment specificity, toward&#xD;
      rotavirus vaccine improvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The work will be carried out in France and in a tropical area of population with diverse&#xD;
      geographical origins: the Guyana populated with Native Americans, people of European descent,&#xD;
      people of Asian (Hmong) and a large source population African.&#xD;
&#xD;
      The first aim of the project will be to characterize the specificity of the VP8 * HBGA of&#xD;
      RotaTeq and Rotarix vaccines in order to ensure their binding characteristics glycans are&#xD;
      similar to those of recent P8 clinical strains circulating in France and were maintained in&#xD;
      the culture passages.&#xD;
&#xD;
      The second objective will be to validate the impact of recently described polymorphisms HBGAs&#xD;
      on susceptibility to infection by RVA through GASTROVIMc prospective clinical research.&#xD;
&#xD;
      The third objective will be to determine the relative role of recognition and HBGAs&#xD;
      ganglioside in the initial attachment and viral entry.&#xD;
&#xD;
      The expression of HBGAs and ganglioside by permissive cell lines in culture human stem RVA be&#xD;
      manipulated to define the role of glycans in attachment and infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Absence / Presence of non-secretory polymorphisms FUT2- and Lewis Negative FUT3-</measure>
    <time_frame>6 months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Population frequency of new protective genotypes to rotavirus infection</measure>
    <time_frame>Six months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence / presence of genetic polymorphisms --other (Including FUT2- and FUT3-)</measure>
    <time_frame>Six months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence / presence of different viral strains Rotavirus (RVA) involved in the acute gastroenteritis episodes in French Guiana</measure>
    <time_frame>Six months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence / presence of various HBGA polymorphisms involved in acute gastroenteritis episodes in French Guiana</measure>
    <time_frame>Six months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>population frequency of different etiologies of acute gastroenteritis viral, bacterial and / or parasitic (Cayenne)</measure>
    <time_frame>Six months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">683</enrollment>
  <condition>Gastroenteritis</condition>
  <condition>Acute Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <description>250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit for diagnosed rotavirus acute gastroenteritis: rotavirus rapid screen test and oral swab for polymorphism exploration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit without signs of infection and / or digestive clinical picture evocative of gastroenteritis.&#xD;
Paired with a case upon ethnicity or origin if impossible to match the ethnicity of the case.&#xD;
oral swab for polymorphism exploration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rotavirus rapid screen test</intervention_name>
    <description>According to routine care</description>
    <arm_group_label>Case group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism exploration</intervention_name>
    <description>from an oral swab collected after parents consent</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Oral swab&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        400 children admitted to the pediatric emergency for acute gastroenteritis (cases) and 400&#xD;
        children admitted to the pediatric emergency without evocative picture of infection or&#xD;
        gastroentieritis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  0 to 16.&#xD;
&#xD;
          -  giving consent to participate if applicable (&gt;6yo)&#xD;
&#xD;
          -  Parents informed and written consent obtained&#xD;
&#xD;
          -  admitted in paediatric emergency for wether an acute gastroenteritis (case group) or&#xD;
             anything else than an infection or gastroenteritis (control group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  case group: rotavirus rapid screen test negative; viral gastroenteritis other than&#xD;
             rotavirus; bacterial gastroenteritis&#xD;
&#xD;
          -  control group: Family and / or patient unable to full informed consent to research;&#xD;
             Infectious Pathology context in general.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christ√®le GRAS-LEGUEN, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Polymorphism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

